Eribulin Mesylate Solution
Product Images NDC 68001-656

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 68001-656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Eribulin Mesylate 1mg-2ml Carton 04-2025 (Eribulin Mesylate 1mg 2ml Carton 04 2025)

Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) intravenous solution packaging label by BluePoint Laboratories. The single-dose vial label includes warnings for cytotoxic agent, dosage and use instructions referring to the prescribing information, and manufacturer details. The label features barcode and NDC 68001-656-41.*

FDA Label Image

Eribulin Mesylate 1mg-2ml Vial Label 04-2025 (Eribulin Mesylate 1mg 2ml Vial Label 04 2025)

Label for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use. The single-dose vial is labeled for use by prescription only and includes storage instructions to keep between 15° to 30°C without freezing or refrigeration. The label notes the product is a cytotoxic agent and manufactured by Cenexi - Laboratories Thissen Sa for BluePoint Laboratories.*

FDA Label Image

Structural Formula (Eri04 0004 01)

Chemical structure of Eribulin Mesylate showing its molecular framework with atoms and bonds, including a methanesulfonic acid (mesylate) group.*

FDA Label Image

Figure 1 (Eri04 0004 02)

A survival curve graph comparing the proportion of patients alive over time in months between two groups: Eribulin Mesylate (N=508) and Control (N=254). The graph shows that patients treated with Eribulin Mesylate have a higher survival proportion across the 36 months observed. The number of patients at risk is tabulated below the x-axis for both groups at various time points.*

FDA Label Image

Figure 2 (Eri04 0004 03)

A Kaplan-Meier survival curve chart comparing survival probabilities over time (months) between Eribulin Mesylate Injection and Dacarbazine. The chart shows survival data, with Eribulin Mesylate represented by a solid blue line and Dacarbazine by a dashed red line. The x-axis indicates survival time in months, and the y-axis shows survival probability. A table below the graph lists the number of subjects at risk over time for both treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.